Covaxin Neutralises Delta Covid Variant: US National Institute of Health.

Covaxin Effectively Neutralises Delta Covid Variant: Top US Health Research Institute

Covaxin has been administered to roughly 25 million people till date in India and elsewhere. (File)

Washington:

India's Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US' National Institute of Health has said.

The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively.

The top American health research institute, which has a history of strong scientific collaboration with India, also said that an adjuvant developed with funding from it has contributed to the success of the highly efficacious Covaxin, which has been administered to roughly 25 million people till date in India and elsewhere.

Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine's effectiveness.

Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus. Published results from a phase 2 trial of the vaccine indicate that it is safe and well tolerated, the NIH said, adding that safety data from a phase 3 trial of Covaxin will become available later this year.

"Meanwhile, unpublished interim results from the phase 3 trial indicate that the vaccine has 78 per cent efficacy against symptomatic disease, 100 per cent efficacy against severe COVID-19, including hospitalisation, and 70 per cent efficacy against asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19," it said.

"The results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively," the NIH said.

Ending a global pandemic requires a global response, said Anthony S Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.

"I am pleased that a novel vaccine adjuvant developed in the US with NIAID support is part of an efficacious COVID-19 vaccine available to people in India," he said.

The adjuvant used in Covaxin, Alhydroxiquim-II, was discovered and tested in a laboratory by the biotech company ViroVax LLC of Lawrence, Kansas with support from the NIAID Adjuvant Development Program.

Alhydroxiquim-II is the first adjuvant in an authorised vaccine against an infectious disease to activate receptors TLR7 and TLR8 that play a vital role in the immune response to viruses.

In addition, the alum in Alhydroxiquim-II stimulates the immune system to search for an invading pathogen. Molecules that activate TLR receptors stimulate the immune system powerfully, but the side effects of Alhydroxiquim-II are mild, the NIH said.

According to the NIH, the NIAID Adjuvant Program has supported the research of the founder and chief executive officer of ViroVax, Sunil David, MD, PhD, since 2009. His work has focused on searching for novel molecules that activate innate immune receptors and developing them as vaccine adjuvants.

The collaboration between Dr David and Bharat Biotech International Ltd. of Hyderabad was initiated during a 2019 meeting in India coordinated by the NIAID Office of Global Research under the auspices of NIAID's Indo-US Vaccine Action Program.

A delegation of five NIAID-funded adjuvant investigators, including Dr David; two members of the NIAID Division of Allergy, Immunology, and Transplantation; and the NIAID India representative, visited four leading biotechnology companies to learn about their work and discuss potential collaborations.

The delegation also attended a consultation in New Delhi co-organised by NIAID and India's Department of Biotechnology and hosted by India's National Institute of Immunology.

Among the scientific collaborations sparked by these activities, Bharat Biotech signed a licensing agreement with Dr David to use Alhydroxiquim-II in their candidate vaccines. This license was expanded during the COVID-19 pandemic to include Covaxin, which has received Emergency Use Authorisation in India and more than a dozen other countries.

"The company conducted extensive safety studies of Alhydroxiquim-II and undertook the complex process of scaling up production of the adjuvant under Good Manufacturing Practice standards. Bharat Biotech expects to produce an estimated 700 million doses of Covaxin by the end of 2021," the NIH said.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV News

NDTV.com provides latest news from India and the world. Get today’s news headlines from Business, Technology, Bollywood, Cricket, videos, photos, live news coverage and exclusive breaking news from India.

https://www.ndtv.com/

Concha on CDC Director Walensky being the 'wrong COVID-19 messenger'.

Concha on CDC Director Walensky being the 'wrong COVID-19 messenger'.

Centers for Disease Control and Prevention Director Rochelle Walensky walks back remarks on vaccine mandate. Fox News contributor Joe Concha weighs in on 'Fox & Friends First.' #FoxNews #FoxFriendsFirst Subscribe to Fox News! Watch more Fox News V...

Texas rancher says his county is at the epicenter of a migrant 'invasion'.

Texas rancher says his county is at the epicenter of a migrant 'invasion'.

Brent Smith, a Texas rancher and Kinney County attorney, details damage due to illegal crossings, noting fences have had to be repaired and some ranchers in the area have had to hire private security 'to defend their own property rights.' Subscrib...

ICE To Begin Processing Migrant Families To Relieve Border Station Overcrowding.

ICE To Begin Processing Migrant Families To Relieve Border Station Overcrowding.

In an unprecedented move, ICE is set to begin processing migrant families at the southern border in an attempt to alleviate overcrowding at patrol stations, according to two Homeland Security officials. NBC News justice correspondent Julia Ainsley...

Turkey wildfires - Terrified tourists airlifted & rescued by boats from Brit resorts killing six.

Turkey wildfires - Terrified tourists airlifted & rescued by boats from Brit resorts killing six.

TOURISTS have been airlifted to safety and rescued by boat from popular Brit resorts near Marmaris as wildfires ravage Turkey - killing at least six people. Frantic photos and videos reveal boats and helicopters rescuing people from beaches in the...

Turkey wildfires: Death toll rises with hundreds injured - DW News.

Turkey wildfires: Death toll rises with hundreds injured - DW News.

The death toll from wildfires in Turkey has increased to eight. Firefighting operations continue on the southern and western coast. The latest victims include a Turkish-German couple who were found in a house, local media reported. Hundreds have b...

Live: New York Gov. Andrew Cuomo Holds Covid-19 Briefing - NBC News

Live: New York Gov. Andrew Cuomo Holds Covid-19 Briefing - NBC News

New York Governor Andrew Cuomo holds a coronavirus briefing and takes questions from reporters. » Subscribe to NBC News: » Watch more NBC video: NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diver...